Abstract
Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it’s associated with HF with preserved ejection fraction (HFPEF).
Keywords: Biomarker, heart failure, parathyroid hormone.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy
Volume: 13 Issue: 1
Author(s): Hakan Altay and Yucel Colkesen
Affiliation:
Keywords: Biomarker, heart failure, parathyroid hormone.
Abstract: Heart failure (HF) is a clinical syndrome featuring cardiac pump failure along with signs and symptoms arising from salt and water retention mediated by activated renin-angiotensin-aldosterone system (RAAS). In addition to this cardiorenal perspective, HF is accompanied by a systemic illness, especially in advanced stages characterized by oxidative stress in various tissues, causing damage to soft tissue and bone. Secondary hyperparathyroidism (SHPT) which is also considered to contribute this systemic illness is therefore prominent in advanced HF. SHPT in HF occurs as a result of RAAS activation, prominent hyperaldosteronism, loop diuretic usage and decreased calcitriol level, all of which results in calcium excretion. We review the evidence that high parathyroid hormone (PTH) is associated with advanced HF, as well as evidence that it’s associated with HF with preserved ejection fraction (HFPEF).
Export Options
About this article
Cite this article as:
Altay Hakan and Colkesen Yucel, Parathyroid Hormone and Heart Failure: Novel Biomarker Strategy, Endocrine, Metabolic & Immune Disorders - Drug Targets 2013; 13 (1) . https://dx.doi.org/10.2174/1871530311313010012
DOI https://dx.doi.org/10.2174/1871530311313010012 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders
Current Drug Targets The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Immunophilins and Cardiovascular Complications
Current Medicinal Chemistry Role of the Sympathetic Nervous Activity in Hypertension-Update in 2013
Current Hypertension Reviews Impact of Ultrasound Contrast Agents in Echocardiographic Assessment of Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery History and Milestones of Mouse Models of Autoimmune Diseases
Current Pharmaceutical Design Relationship between Diabetes Mellitus and Coronary Heart Disease
Current Diabetes Reviews Tanshinone IIA: Pharmacology, Total Synthesis, and Progress in Structure-modifications
Current Medicinal Chemistry Synthetic Routes to Spirocyclic Pyridazines, Partially-Saturated Pyridazines and Their Condensed Derivatives
Current Organic Chemistry Current Therapeutic Strategies and Future Perspectives for the Prevention of Arterial Thromboembolism: Focus on Atrial Fibrillation
Current Pharmaceutical Design Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Impact of N-acetylcysteine and Etodolac Treatment on Systolic and Diastolic Function in a Rat Model of Myocardial Steatosis Induced by High-Fat-Diet
Endocrine, Metabolic & Immune Disorders - Drug Targets Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research Inflammation and Arterial Hypertension: From Pathophysiological Links to Risk Prediction
Current Medicinal Chemistry The Role of Mitochondrial Dysfunction in Heart Failure and Potential Therapeutic Targets
Current Pharmaceutical Design HSP70 Family in the Renal Inflammatory Response
Inflammation & Allergy - Drug Targets (Discontinued) Epidemiology of Hypertension and Diabetes Mellitus in Latin America
Current Hypertension Reviews Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Interception of Cocaine by Enzyme or Antibody Delivered with Viral Gene Transfer: A Novel Strategy for Preventing Relapse in Recovering Drug Users
CNS & Neurological Disorders - Drug Targets New Approaches to the Modulation of the Cyclooxygenase-2 and 5-Lipoxygenase Pathways
Current Topics in Medicinal Chemistry